System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maria Vittoria Cossu is an expert in Infectiology at Luigi Sacco Hospital (Italy). Maria Vittoria Cossu has authored 134 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 4 of them ongoing. SLR score: 454 (community average: 125). How the SLR is computed.

LeadR Profile

Maria Vittoria Cossu Luigi Sacco Hospital Italy
454 ScienceLeadR Reputation 454

Unlock

Register Login
Network Map

Infectiology

Subspecialties: Pharmacy - Public Health - Urology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2011 - 2026
Source: PubMed

Luigi Sacco Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 134

Citations

Citations: 1 715 1st author: 10 Last author: 7 Unique author: 0

Main journals

J Antimicrob Chemother 11
The Poster 8
J Acquir Immune Defic Syndr 7
HIV Med 6
J Infect 6

Best Journals

J Infect 2
Intensive Care Med 1
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Therapeutic drug monitoring uncovering incorrect antiretroviral drug intake in a patient with swallowing difficulties.
PMID 42763503 — darunavir, pharmaceutical preparations, drug monitoring, therapeutics, deglutition		IDCases20260
High frequency of isavuconazole use over voriconazole for chronic pulmonary aspergillosis: a retrospective observational study on tolerability and therapeutic drug monitoring.
PMID 42747415 — voriconazole, pharmaceutical preparations, drug monitoring, drug therapy, pulmonary aspergillosis, drug-related side effects and adverse reactions, therapeutics, drug costs, aspergillosis, antiviral agents		Antimicrob Agents Chemother20260
Real-world use of novel β-lactams in immunologically vulnerable patients: insights from an Italian retrospective cohort.
PMID 42639064 — aged, therapeutics, immunosuppression therapy, lactams		JAC Antimicrob Resist20260
Obesity at antiretroviral therapy initiation and long-term risk of cardiovascular disease, cancer, or death in people with HIV in Italy: a prospective cohort study.
PMID 42633417 — cardiovascular diseases, neoplasms, cohort studies, aged, obesity, therapeutics		EClinicalMedicine20260
Differential pharmacokinetic decay of long-acting cabotegravir and rilpivirine after missed injections: a case series.
PMID 42576789 — injections, drug therapy, rilpivirine		J Antimicrob Chemother20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 3
Phase 2/Phase 3 2
Phase 3 2

By status:

Active not recruiting 5
Completed 2

By type:

Interventional 7

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 7

Main Topics

Cohort/Consortium Investigators 10

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Early DOlutegravir LAmivudine Switching after virological suppression (EDOLAS Study)
2024-518909-18-00 — hiv-1, safety, pharmaceutical preparations, lamivudine, hiv, rna, dolutegravir		Phase 3Active not recruiting2021
A Multicenter Randomized Double Blind Placebo controlled Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Participants living with Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment
2023-509588-25-00 — safety, hepatitis b virus, herpesviridae infections, hepatitis, chronic, herpesvirus 1, cercopithecine, hiv, viruses, therapeutics, hepatitis b, hepatitis b, chronic, infections, hepatitis, virus diseases		Phase 2Active not recruiting2025
Proof of concept treatment study of orally administered VH4004280 or VH4011499 in HIV 1 infected adults
2023-505350-18-00 — hiv-1, safety, capsid, hiv, therapeutics, hiv infections, antiviral agents, infections, pharmacokinetics		Phase 2Active not recruiting2023
Study to Compare Bictegravir Lenacapavir Versus Current Therapy in People With HIV 1 Who Are Successfully Treated With a Complicated Regimen
NCT05502341 — delavirdine, enfuvirtide, darunavir, hiv-1, tenofovir, nelfinavir, safety, chemokines, antibodies, lamivudine, zidovudine, saquinavir, anti-retroviral agents, tablets, rna-directed dna polymerase, food, fumarates, hiv, indinavir, nevirapine, rilpivirine, lopinavir, emtricitabine, peptide hydrolases, integrase inhibitors, antibodies, monoclonal, protease inhibitors, therapeutics, maraviroc, reverse transcriptase inhibitors, infections, integrases, dolutegravir, abacavir		Phase 2/Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS